Status:
RECRUITING
Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection
Lead Sponsor:
National Taiwan University Hospital
Conditions:
H. Pylori Infection
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance. Recent randomized tr...
Detailed Description
Background: Bismuth quadruple therapy is currently the recommended first-line regimen for Helicobacter pylori (H. pylori) infection in regions with high clarithromycin resistance. Recent randomized tr...
Eligibility Criteria
Inclusion
- Patients with naive H. pylori infection
- Subjects with over 20 years old
Exclusion
- Younger than 20 years old
- Ever received H. eradication therapy
- ever received total or subtotal gastrectomy in the past
- Severe chronic disease, such as end stage renal disease, liver cirrhosis, incurable malignant tumors
- Women who are pregnant or breastfeeding
- Those who are not suitable to receive study drugs: such as a history of allergies to study drugs or serious side effects, etc.
- Patients with chronic hepatitis (AST or ALT \>40 IU/L)
- Subjects who cannot sign informed consent by themselves
Key Trial Info
Start Date :
March 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04713670
Start Date
March 10 2021
End Date
December 1 2026
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan